BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:14 PM
 | 
Nov 18, 2008
 |  BC Extra  |  Clinical News

XTL falls on bicifadine data

XTL (NASDAQ:XTLB; Tel Aviv:XTL) fell $2.11 (94%) to $0.12 on Tuesday after top-line data from a double-blind Phase IIb trial in 351 patients with...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >